All NASDAQ BioPharm News, Events, Reports, Sec Filling en-USSun, 08 Mar 2026 06:55:29 GMTrfeed v1.1.1https://github.com/svpino/rfeed/blob/master/README.mdhttps://www.globenewswire.com/news-release/2026/03/07/3251417/0/en/A-Record-Setting-Saturday-as-Broad-Arrow-Closes-107M-Amelia-Concours-Auction-with-6-605-000-Lamborghini-Miura-SV.htmlA Record-Setting Saturday as Broad Arrow Closes $107M+ $Amelia Concours Auction with $6,605,000 Lamborghini Miura SV2Sat, 07 Mar 2026 22:15:00 GMThttps://www.globenewswire.com/news-release/2026/03/07/3251417/0/en/A-Record-Setting-Saturday-as-Broad-Arrow-Closes-107M-Amelia-Concours-Auction-with-6-605-000-Lamborghini-Miura-SV.htmlhttps://www.prnewswire.com//news-releases/investor-notice-navan-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302707152.htmlINVESTOR NOTICE: Navan, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit 2Sat, 07 Mar 2026 18:10:00 GMThttps://www.prnewswire.com//news-releases/investor-notice-navan-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302707152.htmlhttps://www.prnewswire.com//news-releases/investor-alert-soleno-therapeutics-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit--rgrd-law-302707373.htmlINVESTOR ALERT: Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law 2Sat, 07 Mar 2026 18:10:00 GMThttps://www.prnewswire.com//news-releases/investor-alert-soleno-therapeutics-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit--rgrd-law-302707373.htmlhttp://www.businesswire.com/news/home/20260306127402/de/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwaIncyte meldet die Zulassung von Zynyz® (Retifanlimab) durch die Europäische Kommission für die Erstlinienbehandlung von fortgeschrittenem Plattenepithelkarzinom des Analkanals (Squamous Cell Carcinoma of the Anal Canal, SCAC)2Sat, 07 Mar 2026 16:00:00 GMThttp://www.businesswire.com/news/home/20260306127402/de/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwahttp://www.businesswire.com/news/home/20260306810946/fr/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwaIncyte annonce l’autorisation par la Commission européenne de Zynyz® (rétifanlimab) pour le traitement de première intention du carcinome épidermoïde avancé du canal anal (SCAC) 2Sat, 07 Mar 2026 16:00:00 GMThttp://www.businesswire.com/news/home/20260306810946/fr/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwahttp://www.businesswire.com/news/home/20260306469017/it/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwaIncyte annuncia lapprovazione da parte della Commissione europea di Zynyz® (retifanlimab) come terapia di prima linea del carcinoma anale a cellule squamose (SCAC) in fase avanzata 2Sat, 07 Mar 2026 16:00:00 GMThttp://www.businesswire.com/news/home/20260306469017/it/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwahttps://www.globenewswire.com/news-release/2026/03/07/3251393/0/zh-hans/Snail-Inc-%E5%AE%A3%E5%B8%83-%E9%A2%82%E9%92%9F%E9%95%BF%E9%B8%A3-Bellwright-%E5%9C%A8-1-0-%E6%AD%A3%E5%BC%8F%E7%89%88%E5%8F%91%E5%B8%83%E5%89%8D%E9%94%80%E9%87%8F%E7%AA%81%E7%A0%B4-100-%E4%B8%87%E4%BB%BD.htmlSnail, Inc. 宣布《颂钟长鸣》(Bellwright) 在 1.0 正式版发布前销量突破 100 万份2Sat, 07 Mar 2026 11:21:00 GMThttps://www.globenewswire.com/news-release/2026/03/07/3251393/0/zh-hans/Snail-Inc-%E5%AE%A3%E5%B8%83-%E9%A2%82%E9%92%9F%E9%95%BF%E9%B8%A3-Bellwright-%E5%9C%A8-1-0-%E6%AD%A3%E5%BC%8F%E7%89%88%E5%8F%91%E5%B8%83%E5%89%8D%E9%94%80%E9%87%8F%E7%AA%81%E7%A0%B4-100-%E4%B8%87%E4%BB%BD.htmlhttps://www.globenewswire.com/news-release/2026/03/07/3251393/0/zh-hant/Snail-Inc-%E5%A0%B1%E5%91%8A-Bellwright-%E5%9C%A8%E5%AE%8C%E6%95%B4-1-0-%E7%89%88%E6%9C%AC%E6%AD%A3%E5%BC%8F%E6%8E%A8%E5%87%BA%E5%89%8D-%E9%8A%B7%E9%87%8F%E5%B7%B2%E8%B6%85%E8%B6%8A-100-%E8%90%AC%E5%A5%97.htmlSnail, Inc. 報告 Bellwright 在完整 1.0 版本正式推出前，銷量已超越 100 萬套2Sat, 07 Mar 2026 11:21:00 GMThttps://www.globenewswire.com/news-release/2026/03/07/3251393/0/zh-hant/Snail-Inc-%E5%A0%B1%E5%91%8A-Bellwright-%E5%9C%A8%E5%AE%8C%E6%95%B4-1-0-%E7%89%88%E6%9C%AC%E6%AD%A3%E5%BC%8F%E6%8E%A8%E5%87%BA%E5%89%8D-%E9%8A%B7%E9%87%8F%E5%B7%B2%E8%B6%85%E8%B6%8A-100-%E8%90%AC%E5%A5%97.htmlhttps://links.sgx.com/1.0.0/corporate-announcements/3C1IL4YHA39P3EYT/607e331b4e414a8a2b5057906c3444c73494d737b6f0b19d968a0e72fb1ed655General Announcement: Lonza Completes its Transformation to a Pure-Play CDMO with Agreement to Divest Health &Capsule 3Sat, 07 Mar 2026 09:53:35 GMThttps://links.sgx.com/1.0.0/corporate-announcements/3C1IL4YHA39P3EYT/607e331b4e414a8a2b5057906c3444c73494d737b6f0b19d968a0e72fb1ed655https://www.bms.com/media/press-releases.htmlBristol Myers Squibb - U.S. FDA Approves Bristol MyersSquibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis2Sat, 07 Mar 2026 03:00:06 GMThttps://www.bms.com/media/press-releases.html;86d64d32-3e3c-42bf-af81-4718a96b3e60https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/U-S--FDA-Approves-Bristol-Myers-Squibbs-Sotyktu-deucravacitinib-for-the-Treatment-of-Adults-with-Active-Psoriatic-Arthritis/default.aspxU.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis2Sat, 07 Mar 2026 02:59:00 GMThttps://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/U-S--FDA-Approves-Bristol-Myers-Squibbs-Sotyktu-deucravacitinib-for-the-Treatment-of-Adults-with-Active-Psoriatic-Arthritis/default.aspxhttp://www.businesswire.com/news/home/20260306816774/en/U.S.-FDA-Approves-Bristol-Myers-Squibb%E2%80%99s-Sotyktu%C2%AE-deucravacitinib-for-the-Treatment-of-Adults-with-Active-Psoriatic-Arthritis/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwaU.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis2Sat, 07 Mar 2026 02:59:00 GMThttp://www.businesswire.com/news/home/20260306816774/en/U.S.-FDA-Approves-Bristol-Myers-Squibb%E2%80%99s-Sotyktu%C2%AE-deucravacitinib-for-the-Treatment-of-Adults-with-Active-Psoriatic-Arthritis/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwahttps://news.bms.com/news/details/2026/U-S--FDA-Approves-Bristol-Myers-Squibbs-Sotyktu-deucravacitinib-for-the-Treatment-of-Adults-with-Active-Psoriatic-Arthritis/default.aspxU.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis2Sat, 07 Mar 2026 02:59:00 GMThttps://news.bms.com/news/details/2026/U-S--FDA-Approves-Bristol-Myers-Squibbs-Sotyktu-deucravacitinib-for-the-Treatment-of-Adults-with-Active-Psoriatic-Arthritis/default.aspxhttps://www.sec.gov/Archives/edgar/data/1297184/000110465926024842/0001104659-26-024842-index.htmZhang Jack Y. 🔴 sold 8.2K shares of Amphastar Pharmaceuticals, Inc. (AMPH) at $19.96 Transaction Date: Mar 04, 2026 | Filing ID: 0248423Sat, 07 Mar 2026 02:58:54 GMThttps://www.sec.gov/Archives/edgar/data/1297184/000110465926024842/0001104659-26-024842-index.htmhttps://www.prnewswire.com//news-releases/apollo-global-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-apollo-global-management-inc---apo-302707317.htmlApollo Global Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Apollo Global Management, Inc. - APO 2Sat, 07 Mar 2026 02:54:00 GMThttps://www.prnewswire.com//news-releases/apollo-global-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-apollo-global-management-inc---apo-302707317.htmlhttps://www.prnewswire.com//news-releases/navan-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-navan-inc---navn-302707316.htmlNavan Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Navan, Inc. - NAVN 2Sat, 07 Mar 2026 02:54:00 GMThttps://www.prnewswire.com//news-releases/navan-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-navan-inc---navn-302707316.htmlhttps://www.prnewswire.com//news-releases/enphase-energy-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-enphase-energy-inc---enph-302707313.htmlEnphase Energy Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Enphase Energy, Inc. - ENPH 2Sat, 07 Mar 2026 02:52:00 GMThttps://www.prnewswire.com//news-releases/enphase-energy-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-enphase-energy-inc---enph-302707313.htmlhttps://www.prnewswire.com//news-releases/corcept-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-corcept-therapeutics-incorporated---cort-302707319.htmlCorcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT 2Sat, 07 Mar 2026 02:52:00 GMThttps://www.prnewswire.com//news-releases/corcept-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-corcept-therapeutics-incorporated---cort-302707319.htmlhttps://www.prnewswire.com//news-releases/kyndryl-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-kyndryl-holdings-inc---kd-302707318.htmlKyndryl Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Kyndryl Holdings, Inc. - KD 2Sat, 07 Mar 2026 02:51:00 GMThttps://www.prnewswire.com//news-releases/kyndryl-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-kyndryl-holdings-inc---kd-302707318.htmlhttps://www.prnewswire.com//news-releases/uniqure-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-uniqure-nv---qure-302707312.htmluniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QURE 2Sat, 07 Mar 2026 02:50:00 GMThttps://www.prnewswire.com//news-releases/uniqure-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-uniqure-nv---qure-302707312.htmlhttps://www.prnewswire.com//news-releases/ultragenyx-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-ultragenyx-pharmaceutical-inc---rare-302707320.htmlUltragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE 2Sat, 07 Mar 2026 02:49:00 GMThttps://www.prnewswire.com//news-releases/ultragenyx-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-ultragenyx-pharmaceutical-inc---rare-302707320.htmlhttps://www.prnewswire.com//news-releases/bellring-brands-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-bellring-brands-inc---brbr-302707315.htmlBellRing Brands Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against BellRing Brands, Inc. - BRBR 2Sat, 07 Mar 2026 02:48:00 GMThttps://www.prnewswire.com//news-releases/bellring-brands-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-bellring-brands-inc---brbr-302707315.htmlhttps://www.prnewswire.com//news-releases/coreweave-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-coreweave-inc---crwv-302707308.htmlCoreWeave Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against CoreWeave, Inc. - CRWV 2Sat, 07 Mar 2026 02:48:00 GMThttps://www.prnewswire.com//news-releases/coreweave-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-coreweave-inc---crwv-302707308.htmlhttp://www.businesswire.com/news/home/20260306114502/de/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwaKlarna Group Plc erläutert die Abläufe beim Auslaufen der Lock-up-Frist am 9. März2Sat, 07 Mar 2026 02:34:00 GMThttp://www.businesswire.com/news/home/20260306114502/de/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwahttps://www.sec.gov/Archives/edgar/data/1858685/000149315226009259/0001493152-26-009259-index.htmDirector Weber Kevin Daniel 🟢 acquired 20.0K shares (1 derivative) of Biofrontera Inc. (BFRI) at $0.90 Transaction Date: Mar 04, 2026 | Filing ID: 0092593Sat, 07 Mar 2026 02:33:07 GMThttps://www.sec.gov/Archives/edgar/data/1858685/000149315226009259/0001493152-26-009259-index.htmhttps://www.sec.gov/Archives/edgar/data/1858685/000149315226009257/0001493152-26-009257-index.htmDirector Luebbert Hermann 🟡 adjusted position in 250.0K shares (3 derivative) of Biofrontera Inc. (BFRI) at $0.90 Transaction Date: Mar 04, 2026 | Filing ID: 0092573Sat, 07 Mar 2026 02:31:43 GMThttps://www.sec.gov/Archives/edgar/data/1858685/000149315226009257/0001493152-26-009257-index.htmhttps://www.sec.gov/Archives/edgar/data/1858685/000149315226009255/0001493152-26-009255-index.htmLeffler Eugene Frederick 🟡 adjusted position in 125.0K shares (3 derivative) of Biofrontera Inc. (BFRI) at $0.90 Transaction Date: Mar 04, 2026 | Filing ID: 0092553Sat, 07 Mar 2026 02:30:26 GMThttps://www.sec.gov/Archives/edgar/data/1858685/000149315226009255/0001493152-26-009255-index.htmhttps://www.sec.gov/Archives/edgar/data/1858685/000149315226009253/0001493152-26-009253-index.htmDirector Lanckriet Heikki 🟢 acquired 20.0K shares (1 derivative) of Biofrontera Inc. (BFRI) at $0.90 Transaction Date: Mar 04, 2026 | Filing ID: 0092533Sat, 07 Mar 2026 02:29:17 GMThttps://www.sec.gov/Archives/edgar/data/1858685/000149315226009253/0001493152-26-009253-index.htmhttp://www.businesswire.com/news/home/20260306367866/fr/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwaKlarna Group Plc clarifie les modalités de lexpiration du lock-up du 9 mars2Sat, 07 Mar 2026 02:29:00 GMThttp://www.businesswire.com/news/home/20260306367866/fr/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwahttp://www.businesswire.com/news/home/20260306507770/en/Investor-Notice-Robbins-LLP-Informs-Investors-of-the-Soleno-Therapeutics-Inc.-Class-Action-Lawsuit/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwaInvestor Notice: Robbins LLP Informs Investors of the Soleno Therapeutics, Inc. Class Action Lawsuit2Sat, 07 Mar 2026 02:29:00 GMThttp://www.businesswire.com/news/home/20260306507770/en/Investor-Notice-Robbins-LLP-Informs-Investors-of-the-Soleno-Therapeutics-Inc.-Class-Action-Lawsuit/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwahttps://www.sec.gov/Archives/edgar/data/1858685/000149315226009251/0001493152-26-009251-index.htmDirector Hoffman Beth J. 🟢 acquired 20.0K shares (1 derivative) of Biofrontera Inc. (BFRI) at $0.90 Transaction Date: Mar 04, 2026 | Filing ID: 0092513Sat, 07 Mar 2026 02:28:12 GMThttps://www.sec.gov/Archives/edgar/data/1858685/000149315226009251/0001493152-26-009251-index.htmhttps://www.sec.gov/Archives/edgar/data/1858685/000149315226009249/0001493152-26-009249-index.htmJones George Patrick 🟢 acquired 100.0K shares (2 derivative) of Biofrontera Inc. (BFRI) at $0.90 Transaction Date: Mar 04, 2026 | Filing ID: 0092493Sat, 07 Mar 2026 02:26:24 GMThttps://www.sec.gov/Archives/edgar/data/1858685/000149315226009249/0001493152-26-009249-index.htmhttps://www.sec.gov/Archives/edgar/data/1858685/000149315226009247/0001493152-26-009247-index.htmDirector BORER JOHN J III 🟢 acquired 20.0K shares (1 derivative) of Biofrontera Inc. (BFRI) at $0.90 Transaction Date: Mar 04, 2026 | Filing ID: 0092473Sat, 07 Mar 2026 02:25:15 GMThttps://www.sec.gov/Archives/edgar/data/1858685/000149315226009247/0001493152-26-009247-index.htmhttps://www.globenewswire.com/news-release/2026/03/07/3251380/0/en/NEWS-FLASH-Broad-Arrow-Smashes-World-Records-with-Collection-of-Unobtanium-Supercars-on-Day-One-of-Amelia-Concours-Auction.htmlNEWS FLASH: Broad Arrow Smashes World Records with Collection of Unobtanium Supercars on Day One of Amelia Concours Auction2Sat, 07 Mar 2026 02:18:00 GMThttps://www.globenewswire.com/news-release/2026/03/07/3251380/0/en/NEWS-FLASH-Broad-Arrow-Smashes-World-Records-with-Collection-of-Unobtanium-Supercars-on-Day-One-of-Amelia-Concours-Auction.htmlhttps://www.sec.gov/Archives/edgar/data/1297184/000164532626000003/0001645326-26-000003-index.htmZhou Rong 🔴 sold 1.1K shares of Amphastar Pharmaceuticals, Inc. (AMPH) at $19.96 Transaction Date: Mar 04, 2026 | Filing ID: 0000033Sat, 07 Mar 2026 02:06:34 GMThttps://www.sec.gov/Archives/edgar/data/1297184/000164532626000003/0001645326-26-000003-index.htmhttps://www.sec.gov/Archives/edgar/data/1297184/000174392726000003/0001743927-26-000003-index.htmLiawatidewi Yakob 🔴 sold 965 shares of Amphastar Pharmaceuticals, Inc. (AMPH) at $19.96 Transaction Date: Mar 04, 2026 | Filing ID: 0000033Sat, 07 Mar 2026 02:04:17 GMThttps://www.sec.gov/Archives/edgar/data/1297184/000174392726000003/0001743927-26-000003-index.htmhttps://www.sec.gov/Archives/edgar/data/1297184/000126313626000003/0001263136-26-000003-index.htmPETERS WILLIAM J 🔴 sold 1.7K shares of Amphastar Pharmaceuticals, Inc. (AMPH) at $19.96 Transaction Date: Mar 04, 2026 | Filing ID: 0000033Sat, 07 Mar 2026 02:02:52 GMThttps://www.sec.gov/Archives/edgar/data/1297184/000126313626000003/0001263136-26-000003-index.htmhttps://www.sec.gov/Archives/edgar/data/1937653/000119312526097240/0001193125-26-097240-index.htm📋 Jeffrey T L Smith (Ex-Officer) plans to sell 247K shares of Zymeworks Inc. (at $24.80 each, total $6.1M) Filed: Mar 06, 2026 | ID: 0972403Sat, 07 Mar 2026 02:00:02 GMThttps://www.sec.gov/Archives/edgar/data/1937653/000119312526097240/0001193125-26-097240-index.htmhttp://www.businesswire.com/news/home/20260306883239/es/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwaKlarna Group Plc aclara los mecanismos de la expiración del bloqueo del 9 de marzo2Sat, 07 Mar 2026 01:25:00 GMThttp://www.businesswire.com/news/home/20260306883239/es/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwahttps://www.sec.gov/Archives/edgar/data/1974640/000110465926024831/0001104659-26-024831-index.htmDambkowski Carl 🟡 adjusted position in 5.5K shares (1 derivative) of Apogee Therapeutics, Inc. (APGE) at $73.26 Transaction Date: Mar 04, 2026 | Filing ID: 0248313Sat, 07 Mar 2026 01:00:10 GMThttps://www.sec.gov/Archives/edgar/data/1974640/000110465926024831/0001104659-26-024831-index.htmhttps://www.sec.gov/Archives/edgar/data/1478320/000123756626000001/0001237566-26-000001-index.htmDirector NEUPERT PETER M 🟢 acquired 15.6K shares of Adaptive Biotechnologies Corp (ADPT) Transaction Date: Mar 04, 2026 | Filing ID: 0000013Sat, 07 Mar 2026 00:59:17 GMThttps://www.sec.gov/Archives/edgar/data/1478320/000123756626000001/0001237566-26-000001-index.htmhttps://www.prnewswire.com//news-releases/elf-beauty-investigation-initiated-kahn-swick--foti-llc-investigates-the-officers-and-directors-of-elf-beauty-inc---elf-302707306.htmle.l.f. Beauty Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of e.l.f. Beauty, Inc. - ELF 2Sat, 07 Mar 2026 00:55:00 GMThttps://www.prnewswire.com//news-releases/elf-beauty-investigation-initiated-kahn-swick--foti-llc-investigates-the-officers-and-directors-of-elf-beauty-inc---elf-302707306.htmlhttps://www.sec.gov/Archives/edgar/data/876343/000119312526097185/0001193125-26-097185-index.htmCulley Brian M 🟢 acquired 3.2M shares (1 derivative) of Lineage Cell Therapeutics, Inc. (LCTX) at $1.84 ($6.0M) Transaction Date: Mar 05, 2026 | Filing ID: 0971853Sat, 07 Mar 2026 00:51:00 GMThttps://www.sec.gov/Archives/edgar/data/876343/000119312526097185/0001193125-26-097185-index.htmhttps://www.sec.gov/Archives/edgar/data/876343/000119312526097184/0001193125-26-097184-index.htmHowe Jill Ann 🟢 acquired 1.1M shares (1 derivative) of Lineage Cell Therapeutics, Inc. (LCTX) at $1.84 ($1.9M) Transaction Date: Mar 05, 2026 | Filing ID: 0971843Sat, 07 Mar 2026 00:50:33 GMThttps://www.sec.gov/Archives/edgar/data/876343/000119312526097184/0001193125-26-097184-index.htmhttps://www.sec.gov/Archives/edgar/data/1478320/000127413926000001/0001274139-26-000001-index.htmDirector HERSHBERG ROBERT 🟢 acquired 15.6K shares of Adaptive Biotechnologies Corp (ADPT) Transaction Date: Mar 04, 2026 | Filing ID: 0000013Sat, 07 Mar 2026 00:49:06 GMThttps://www.sec.gov/Archives/edgar/data/1478320/000127413926000001/0001274139-26-000001-index.htmhttps://www.sec.gov/Archives/edgar/data/876343/000119312526097181/0001193125-26-097181-index.htmSamuel George A. III 🟢 acquired 900.0K shares (1 derivative) of Lineage Cell Therapeutics, Inc. (LCTX) at $1.84 ($1.7M) Transaction Date: Mar 05, 2026 | Filing ID: 0971813Sat, 07 Mar 2026 00:48:56 GMThttps://www.sec.gov/Archives/edgar/data/876343/000119312526097181/0001193125-26-097181-index.htmhttps://www.sec.gov/Archives/edgar/data/1865782/000090883426000130/0000908834-26-000130-index.htmGreenwell Scott A. 🟢 acquired 69.1K shares (1 derivative) of BrightSpring Health Services, Inc. (BTSG) at $41.77 ($2.0M) Transaction Date: Mar 05, 2026 | Filing ID: 0001303Sat, 07 Mar 2026 00:46:31 GMThttps://www.sec.gov/Archives/edgar/data/1865782/000090883426000130/0000908834-26-000130-index.htmhttps://www.sec.gov/Archives/edgar/data/1865782/000090883426000128/0000908834-26-000128-index.htmROUSSEAU JON B 🟡 adjusted position in 468.4K shares (5 derivative) of BrightSpring Health Services, Inc. (BTSG) at $41.77 ($42.9M) Transaction Date: Mar 04, 2026 | Filing ID: 0001283Sat, 07 Mar 2026 00:45:35 GMThttps://www.sec.gov/Archives/edgar/data/1865782/000090883426000128/0000908834-26-000128-index.htmhttps://www.sec.gov/Archives/edgar/data/1865782/000090883426000127/0000908834-26-000127-index.htmPhipps Jennifer A 🟡 adjusted position in 190.5K shares (4 derivative) of BrightSpring Health Services, Inc. (BTSG) at $41.77 ($7.6M) Transaction Date: Mar 04, 2026 | Filing ID: 0001273Sat, 07 Mar 2026 00:45:12 GMThttps://www.sec.gov/Archives/edgar/data/1865782/000090883426000127/0000908834-26-000127-index.htmhttps://www.sec.gov/Archives/edgar/data/1865782/000090883426000126/0000908834-26-000126-index.htmBarnes Robert Allen 🟢 acquired 38.3K shares (2 derivative) of BrightSpring Health Services, Inc. (BTSG) at $7.01 Transaction Date: Mar 04, 2026 | Filing ID: 0001263Sat, 07 Mar 2026 00:44:44 GMThttps://www.sec.gov/Archives/edgar/data/1865782/000090883426000126/0000908834-26-000126-index.htm